The drugmaker's lead product, Rasuvo, is an injectable version of a commonly prescribed drug used to treat rheumatoid arthritis.
The agency launched a giving campaign to celebrate the life of Christophe Foultier.
FDA advisers vote against BioMarin's Duchenne drug; the FDA approves Lilly's lung-cancer drug; criticism mounts for Pfizer's proposed deal with Allergan
The year 2015 may have lacked a hall-of-fame debut on par with 2014's hep.-C launches, but the year featured its share of intrigue in the form of sky-high valuations forcing big organizations to adjust their M&A approach and more. In this Q&A, Jon Gardner, deputy news editor at EvaluatePharma's EP Vantage, reads the tea leaves and hands out some awards—including Company of the Year honors for a controversial candidate
The contract sales organization plans to sell its commercial services business to Publicis Healthcare Communications Group.
If value-based care represents the future of healthcare, it needs a better definition, attendees at an HHS forum said.
Opdivo receives another indication; increasing generic prescriptions may boost patient adherence; hep.-C drugs should be prescribed during earlier stages of disease
A peek at 159 aspiring agents, with profiles on 17 that could shoot to stardom. Rebecca Mayer Knutsen has the forecast
The deal is estimated to bring in $2 billion in operational synergies, in addition to further commercializing Allergan's products outside the US.
Pfizer/Allergan merger creates world's largest drugmaker; Turing cuts Daraprim price for hospitals; CVS to cover Amgen's PCSK9 inhibitor
To hear politicians tell it—especially the ones seeking President Obama's job—pharma is motivated by profit and needs to be brought to heel. The reality of the situation, inside DC and out, is just a tad more complex. Larry Dobrow takes a closer look at what might be coming down the policy pipeline Illustration by Alex Fine
AstraZeneca and Sanofi to share compounds in rare agreement; FDA advisory committee votes against bladder cancer drug; Allergan may buyer in Pfizer deal
Six employees from the Paris-based agency networks lost their lives in the attacks on Friday.
Pfizer reportedly nears deal with Allergan; health insurers are to blame for rising healthcare costs, according to report; a new fund seeks to invest in digital bio start-ups
Specialty medicines will keep drug spend trending upward through the next five years.
If more physicians begin participating in late-phase research efforts—and work to educate patients about these opportunities—we can expect new innovations in treatment solutions to come more quickly to market.
Califf defends his past; Drug spending to increase by 4%-7% per year through 2020; Samsung Bioepis's Enbrel biosimilar faces decision-date Friday
The American Medical Association voted in support of banning DTC advertising.
There is an immediate need for greater education regarding halal and vaccines for Muslim consumers worldwide.
Addyi off to a slow start; Dr. Robert Califf faces Senate committee on FDA nomination; FDA grants Opdivo Breakthrough Therapy Designation in kidney cancer
Havas Health acquired Lexington, Kentucky-based agency Symbiotix.
Although the industry wants to help patients get healthy - and wants to be a critical part in that process - there's a delicate balance to strike between selling product and achieving healthier outcomes.
PBMs crack down on specialty pharmacies; Merck's cholesterol drug soldiers on; rare-disease drug nabs approval
Harvoni's label is expanded; AstraZeneca lung-cancer drug receives accelerated approval; Mylan's Perrigo takeover falls short
Some pharma companies are taking steps to address concerns about the high prices of drugs at a time when Democratic lawmakers are urging price controls.
The embroiled drugmaker now faces allegations that it violated securities law and that its staff was embedded in Philidor's day-to-day operations.
Not-for-profit ranks Gilead Sciences and Sanofi as the lowest-scoring drugmakers in terms of clinical trial transparency; Perrigo shareholders to vote on Mylan deal; new Valeant allegations
If approved, AstraZeneca's investigational antibody anifrolumab would compete with GlaxoSmithKline's Benlysta to treat lupus.
Dr. Reddy's is blocked from selling generic purple Nexium; the FDA approves Roche's melanoma drug; Novartis says Entresto keeps heart-failure patients from being readmitted to the hospital
Aggressive treatment of blood pressure reduces deaths; AstraZeneca's experimental lupus drug cut disease activity in trial; Sophiris Bio reports results for enlarged prostate drug
Soon, IBM says, Watson will be used by one particular pharma company to create a website where, once a drug is prescribed, patients can ask questions in their own words and the website will provide answers in near real-time.
The company "embraces" adverse-event reporting and knows not to expect monetary ROI from unbranded initiatives, says its US-based social media lead.
More patients may be eligible for new PCSK9 inhibitors; Collegium's painkiller may receive FDA approval; MannKind's Afrezza reports slow sales
Test your knowledge in this week's edition of the MM&M Weekly News Quiz.
Obama administration tells states they cannot restrict hep-C drugs; AstraZeneca says it will acquire ZS Pharma: Allergan CEO says drug discovery is too risky
A pair of surveys paint a complicated picture of what direction pharma access to healthcare providers is going.
Not only are men more receptive to pharmaceutical advertising than previously thought, they are also more active in researching medical conditions and treatments
Pfizer increases the financial assistance it gives to patients; Senate committee opens investigation into drug pricing; OptumRx reportedly stopped business with Philidor a year ago
Executives at Eli Lilly, Merck and Biogen used the most recent earnings season to promote innovation and defend drug pricing.
It marks the agency's second acquisition in seven months.
Many patients allow doctors to access their social-media accounts; Turing will reportedly lower the price of Daraprim by 10%; WebMD reports boost in traffic
The public said drugmakers spend too much money on marketing to doctors and patients
GSK partners with other drugmakers to bolster pipeline; Pfizer makes deal in South Africa for Prevnar 13; the FDA issues guidance on HIV biologic development
Interpublic's dedicated group extended its brief beyond North America.
Shire said it will acquire Dyax, which markets Kalbitor; Citron doesn't plan to release any additional allegations against Valeant; Myriad Genetics launches social-media campaign
The neurology space is gearing up to shake free of its decade-long stagnancy, with sector leaders and runners-up alike angling to push the boundaries. What that means: Imminent advances in genetic sequencing, targeted treatments and diagnostics, all designed to get to the biological root of neurological disorders. Rebecca Mayer Knutsen explains
Jaimy Lee talks with Sudler & Hennessey's Rob Rogers, 2015 Lions Health pharma jury president, about what made this campaign worthy of a trophy, and what the win says about the ongoing debate about creativity versus conservatism in pharma advertising.
Patient portals are an underutilized resource for a population hungry for health information.
Test your knowledge in this week's edition of the MM&M Weekly News Quiz
Valeant cuts ties with Philidor; federal officials arrest former Warner Chilcott president over kickback charges; researchers question accuracy of media report that describe drugs as miracles
Initiatives in Europe follow the US example when it comes to requiring manufacturers to report information about financial relationships with physicians.
The campaign marks the drugmaker's foray into oncology DTC advertising as it vies for market share against competing treatment Keytruda.
Work hard to get everyone in your company to understand what you can learn from social listening—you'll know you're successful when inquisitive minds throughout the company start asking you the question, "Can we find out what patients are saying about this brand online?"
Pfizer in merger talks with Allergan; comparative effectiveness council says PCSK9s aren't worth the money; pharmacy tied to Valeant used "back-door" sales tactics
The drugmaker had sued the FDA in September over marketing restrictions for its painkiller, Exparel.
Walgreens buys Rite Aid in $9.4 billion deal; Arena fires a third of its workforce and discontinues Belviq clinical trials; FDA approves Amgen melanoma immunotherapy
To date, pharma marketers have viewed interactive video as more or less a curio—a tactic best assigned to next year's to-do list. But in doing so, they're missing a huge opportunity to connect in ways that more linear forms of advertising can't match. By way of IKEA and Coldplay, Mitch Apley explains
Company's vaccines chief credits campaigns aimed at grownups with driving US demand for blockbuster vaccine. The remaining cohort will be harder to capture.
The drugmaker said Entresto, its new heart-failure drug, brought in "modest sales" in the third quarter of 2015.
Oncologist perception of diagnostics may grow as immuno-oncology treatments move toward first-line use, drugmaker execs say.
Novartis to pay $390 million to settle a lawsuit over drug sales; researchers examine why some patients respond better than others to immuno-oncology drugs; experimental heart-failure drug to get late-stage trial
As pharma marketers continue on their age-old quest to engage physicians, the either/or choice between reps and digital tactics has largely gone away in favor of programs that incorporate both. At the same time, certain segments of the business are still finding their way in the brave new digital world. Larry Dobrow surveys the scene
Valeant made the disclosure as it defends its accounting practices and relationships with specialty pharmacies.
A powerful opportunity has emerged to publish content directly on LinkedIn in order to increase the visibility of a company's corporate narrative and services as part of an integrated marketing strategy that spans paid, owned and earned media.
FDA panel recommends AZ gout drug for approval; Valeant to form committee to examine specialty pharmacy ties; patients treated with Keytruda had longer survival than those who took chemo
Programmatic buying has started to take over the placement of digital ads, to the tune of $15 billion in 2015 sales. Is pharma in the process of following suit or will concerns about privacy and fraud dampen industry enthusiasm? Barbara Peck assesses the pros and cons
Amgen reportedly asks Repatha patients seeking financial assistance for personal health information; Valeant faces more scrutiny of business model; the FDA approves new J&J cancer drug
Test your knowledge in this week's edition of the MM&M Weekly News Quiz
Three suggestions for defusing the highly charged pricing atmosphere
"Gene therapy is a collection of small details. It's not a secret sauce."
The drugmaker recently launched a DTC campaign for diabetes drug Trulicity, which generated $73.7 million in sales in the third quarter.
One analyst said he expects that the change in label "will meaningfully commercially impair Viekira Pak sales."
Theranos posted the lengthy response on the news section of its website on Thursday, then bragged on Twitter that its statement was 3,000 words longer than the WSJ story.
Theranos defends its blood tests; Perrigo slims workforce in response to Mylan bid; Obama wants to double doctors to prescribe opioid-addiction drugs
The company plans to run the campaign through 2016 to counteract slowing sales for Tecfidera.
The deal combines two of Merck's wholly owned subsidiaries.
23andMe relaunches its DTC genetic test; Valeant's woes increase as shares plummet; the FDA questions the safety of AstraZeneca's gout drug
Pharma's internal innovation units often look externally for ideas that can transform the business. Here, the director of Pfizer's worldwide innovation group describes how he imported an approach to help sustain skill development within the network.
The drugmaker, which recently drew scrutiny from lawmakers, is planning to change some of its most contentious business practices. Experts say Valeant also needs to educate lawmakers and the public about the value of its medicines.
Therapy and low-dose drugs found to aid schizophrenia patients more than just antipsychotics; Clinton calls for investigations into drug price increases; Bayer issues RFP for AOR for consumer care brands
The independent agency hired ICC Lowe executive Martin Mannion.
The drugmaker aims to differentiate its type-2 diabetes drug in the competitive GLP-1 receptor agonist class.
The FDA approves Pradaxa antidote; Valeant CEO says he expects a new pricing environment in 2016; FDA denies Shire dry-eye drug
From clinical trials to customer planning, digital can speed the biopharma product launch at each step, said Nancy Phelan, BMS head of commercial operations, at last week's MM&M Leadership Exchange.
The NIH plans to fund fewer but more meaningful studies; the FDA asks for more data about AstraZeneca diabetes drug; payers continue to deny coverage for new hep.-C treatments
Attention turns to Valeant, which is facing subpoenas from two attorneys general who are seeking information about the drugmaker's patient-assistance, drug-pricing and drug-distribution practices.
Sherry Goldberg will replace her as New York market leader.
Valeant receives subpoenas over drug pricing; BMS signs new immuno-oncology deal with Five Prime Therapeutics; Pfizer CEO says insurance coverage to blame in price debate
Bristol-Myers Squibb's Opdivo expanded indication in lung cancer could push Keytruda to the margins.
This year's inductees are C.Marshall Paul and Scott Cotherman. Ken Begasse Sr. will receive the 2016 Lifetime Achievement Award.
J&J should pursue tuck-in deals; Lilly offers online college course about drug development; Clinton and Sanders identify drugmakers as political enemies
Lilly stops trial for experimental heart drug; Turing misses deadline to respond to lawmakers about price increase of Daraprim; the FDA expands indication for Opdivo
Kristie Kuhl, previously EVP at Cohn & Wolfe, is tasked with building out the agency's pharmaceutical business.
Test your knowledge in this week's edition of the MM&M Weekly News Quiz.
Critics question the FDA's decision to approve OxyContin for children; AstraZeneca temporarily stops to lung-cancer trials; Sanders will oppose Califf's nomination as FDA commissioner
Part of the challenge for drugmakers, medical-device makers and healthcare providers is finding the right digital talent and advocating for cultural changes within their organizations.
Sanofi's Aubagio reduces brain volume loss; cancer specialists avoid pricey cancer meds; analysis says placebo effect is on the rise
The drugmakers worked with Evoke Health to develop a campaign that would differentiate the third-in-class type-2 diabetes drug in an increasingly competitive market.
Califf reportedly removes name from research questioning FDA oversight of clinical trials; Express Scripts to cover both PCSK9 inhibitors; trial for experimental cancer drug halted after patient death
Content marketing is not advertising in the old sense. In its use of social media, content marketing challenges consumers while relying on their input. It is proactive and responsive to their concerns, needs and energy. Content marketing has become the new voice of marketing. Learn what you need to know and how pharma marketers can adapt to this innovative venture into social media by clicking here for access.